secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2026-08-06T20:11:40+00:00
Accession:  0001193125-26-338019
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Q2 net loss $110.7M; NDA for azetukalner on track for Q3 2026
-------------------------------------------------------------------

- Net loss of $110.7M in Q2 2026 vs $84.7M in Q2 2025; R&D expenses rose to $99.2M.
- Cash and securities $1.245B as of June 30, 2026; cash runway into 2029.
- NDA submission for azetukalner in FOS remains on track for Q3 2026 after pre-NDA meeting with FDA.
- Phase 3 X-NOVA2 topline data in MDD expected H1 2027; X-TOLE3 and X-ACKT enrollment ongoing.
- Phase 1 studies for XEN1701, XEN1720 (NaV1.7) and XEN1120 (KV7) expected to complete H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526338019/0001193125-26-338019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526338019/xene-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer